Story perspectives

Dengue Vaccine Qdenga Shows 7-Year Protection, Boosting Hope

11/5/2025

30 4

Summary

Story summary

Takeda Pharmaceutical's dengue vaccine Qdenga showed seven years of protection against infection and hospitalization in a phase-3 study of over 20,000 participants in dengue-endemic regions, with 61.2% efficacy and 74.3% after a booster.
The vaccine has been administered globally, with over 18 million doses in 41 countries.
Qdenga is not yet approved in the United States.
The dengue rise driven by climate change underscores the need for prevention in Brazil.

1 of 1

Story summary

Takeda Pharmaceutical's dengue vaccine Qdenga showed seven years of protection against infection and hospitalization in a phase-3 study of over 20,000 participants in dengue-endemic regions, with 61.2% efficacy and 74.3% after a booster.
The vaccine has been administered globally, with over 18 million doses in 41 countries.
Qdenga is not yet approved in the United States.
The dengue rise driven by climate change underscores the need for prevention in Brazil.